Get to know our clinical trials
Trial to compare targeted intratumoral placement of phosphor-32 phosphor-32 (OncoSil) together with FOLFIRINOX and FOLFIRINOX chemotherapy as sole treatment in patients with locally advanced unresectable pancreatic adenocarcinoma.
EL OBJETIVO DE ESTE ESTUDIO DE INVESTIGACIÓN ES EVALUAR LA SEGURIDAD Y LA EFICACIA DE UN PRODUCTO SANITARIO RADIACTIVO IMPLANTABLE, ONCOSIL¿, CUANDO SE IMPLANTA EN PACIENTES CON CÁNCER DE PÁNCREAS, QUE ESTÁN RECIBIENDO LA QUIMIOTERAPIA DE REFERENCIA DENOMINADA FOLFIRINOX
Technical Summary
- AN OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO COMPARE TARGETED INTRATUMORAL PLACEMENT OF PHOSPHOROUS-32 (ONCOSIL¿) IN CONJUNCTION WITH FOLFIRINOX (TRIPPFFX, ACRONYM FOR TARGETED INTRATUMOURAL PLACEMENT OF PHOSPHOROUS- 32 (ONCOSIL¿) IN ADDITION TO FOLFIRINOX) AND FOLFIRINOX CHEMOTHERAPY AS THE SOLE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC ADENOCARCINOMA.
- Code EudraCT: -
- Protocol number: ONCO01P04
- Promoter: OncoSil Medical, Ltd.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.